BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 10, 2026
Home » Topics » Coronavirus, BioWorld

Coronavirus, BioWorld
Coronavirus, BioWorld RSS Feed RSS

COVID-19 vials shaped as dollar sign

Downturn in US demand leads to course correction for COVID-19 vaccines, therapy

Oct. 16, 2023
By Mari Serebrov
The vagaries of the COVID-19 market and the uncertainties of pandemic fatigue are hitting some biopharma companies in the pocketbook, at least for now. Due to lower-than-expected revenues from its COVID-19 Comirnaty vaccine and antiviral Paxlovid (nirmatrelvir/ritonavir), Pfizer Inc. reduced its 2023 revenue guidance by $9 billion after hours Oct. 13, saying it now anticipates full-year 2023 revenues to range from $58 billion to $61 billion – down from its previous guidance range of $67 billion to $70 billion.
Read More

In the clinic for Oct. 16, 2023

Oct. 16, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 60 Degrees, Abion, Almirall, Anixa, Arcutis, Aslan, Foresee, Genentech, Harmony, Incyte, Inmagene, Leo, Meiji Seika, Nektar, Nerviano, Nuvalent, PMV, Relay, Repare, Sanofi, Sotio, Stellas, Theratechnologies, Tiziana, Trevi, UCB.
Read More
Earth infected with pandemic

IDWeek 2023: Next pandemic preparedness – how to forecast and prevent

Oct. 16, 2023
By Coia Dulsat
In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Read More

In the clinic for Oct. 12, 2023

Oct. 12, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Almirall, AM-Pharma, Amylyx, Biocardia, BMS, Codagenix, Cytovation, Faron, Galderma, Genentech, Gritstone, Immunic, Incyte, Index, Leo, Maia, MC2, Merck KGaA, Novo Nordisk, PDS, Puretech, Sellas, Shionogi, Sotio, Tempest, Vyluma.
Read More

Other news to note for Oct. 10, 2023

Oct. 10, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Almirall, Berlin Cures, Biomap, Canariabio, Centrient, Couragen, GPCR, Hikma, Kamada, Ocugen, Pharmenable, Salipro, Sosei, Stem, Theramex, Venatorx, Verge, XNK.
Read More

Regulatory actions for Oct. 5, 2023

Oct. 5, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acrotech, Bioxcel, Inhibikase, Novavax, Noxopharm, Takeda, Theratechnologies, Transcenta, Vedanta.
Read More

In the clinic for Oct. 5, 2023

Oct. 5, 2023
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akero, Ardelyx, Biomx, Blue Earth, Clearside, Freeline, Gain, Moderna, Ocular, Oncoinvent, Regenxbio, Rejuvenate, Starton, Swanbio, Vedanta, Vertex, Veru.
Read More

Other news to note for Oct. 4, 2023

Oct. 4, 2023
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Actinium, Adolore, Aerium, Anagram, Ankyra, Arcalis, Arcturus, Atum, Capsida, Codagenix, Esperovax, Eton, Exscientia, Flightpath, FSD, Harrington, HDT, Imidomics, Intellia, J&J, Kate, Kezar, Klogenix, Merck & Co., Neurodon, Novartis, Oakrum, Oryzon, Pharmaessentia, Phaxiam, Regeneron, Sandoz, Sanofi, Shasqi, Strm.bio, Ubiquigent, Vetophage, Vir, Wuxi.
Read More

Regulatory actions for Oct. 2, 2023

Oct. 2, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amicus, Biontech, Capricor, Erydel, Geron, Hutchmed, Outlook, Pfizer, Quince, Regeneron, Takeda.
Read More
Nobel Prize graphic with illustrations of Katalin Karikó and Drew Weissman
Infection

Perseverance on mRNA therapy research wins the 2023 Nobel Prize in Medicine after saving millions of lives

Oct. 2, 2023
By Mar de Miguel
Researchers who follow their instincts and achieve slow results while trying to break barriers have little support. They replace it with persistence. This is the story of Katalin Karikó and Drew Weissman. What was once a dream in their minds was later a success. Their work together for decades was essential to achieving mRNA vaccines, and their perseverance was rewarded today with the 2023 Nobel Prize in Medicine.
Read More
Previous 1 2 … 13 14 15 16 17 18 19 20 21 … 357 358 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing